case_images: PMC4937497_01
case_images: Prothrombin time/international normalized ratio (PT/INR) values and serum carcinoembryonic antigen (CEA) levels during regorafenib treatment. Only an important points are mentioned PT/INR values (day on course) after co-administration of regorafenib
case_images: 40780_2016_50_Fig1_HTML.jpg
case_images: PMC4937497_01_40780_2016_50_Fig1_HTML.jpg
case_images: Fig1
case_images: The warfarin dose was increased up to 1.5 mg one month before initiation of treatment with regorafenib and up to 2 mg again when regorafenib was given concurrently (Fig. 1). Although the patient's PT/INR value was 1.26 before initiation of treatment with regorafenib, this value significantly increased to 2.1 on day 8, 2.98 on day 15, and 6.4 on day 22 (Fig. 1). His PT/INR value increased to 3.37 again on day 8 after restarting treatment with regorafenib (Fig. 1).